Dispensing method for realizing diversified preparation of medicines

Abstract

The invention belongs to the technical field of pharmaceutical engineering and medical technology, and discloses a medicine dispensing method for realizing diversified preparation of medicines, which comprises the following steps: acquiring prescription information of a patient, determining physical morphological characteristics and chemical stability characteristics of the medicines, and determining individualized adjustment factors of the medicines; generating a dispensing sequence table according to the individualized adjustment factors and the physical morphological characteristics; based on the dispensing sequence table and the chemical stability characteristics, determining an isolation demand level, and distributing a dispensing operation interval according to the isolation demand level; determining a dose segmentation mode of each medicine, and performing dose segmentation on each medicine according to the dose segmentation mode; performing dynamic compatibility verification on the dose segmentation results, and after the verification is passed, combining and packaging all the dose segmentation results so as to obtain a customized medicine combination of the patient; and a technical support is provided for implementation of a precise medical idea in medicine service.

Description

Technical Field

[0001] This invention relates to the fields of pharmaceutical engineering and medical technology, and more specifically, to a drug preparation method for achieving diversified drug formulation. Background Technology

[0002] With the accelerating aging of the population and the continuous rise in the incidence of chronic diseases, the demand for personalized medication is increasing daily. The precision and diversification of drug preparation have become core elements of the modern medical service system. In clinical practice, in order to meet the specific treatment needs of patients and improve medication adherence, customized drugs with multiple drug components have gradually become an important service provided by medical institutions and retail pharmacies. In particular, for elderly patients with multiple coexisting diseases, pediatric patients, and special populations, personalized drug preparation based on their physiological characteristics, metabolic capacity, and treatment needs is of great significance for improving treatment effects, reducing adverse drug reactions, and optimizing the medication experience.

[0003] However, existing drug dispensing technologies have significant technical bottlenecks in the automated and precise dispensing of complex prescriptions. This problem is particularly prominent in outpatient pharmacies and pharmacy departments of large hospitals during peak periods. Specifically, when a single prescription requires the dispensing of more than six drugs and some drugs require precise dosage adjustments, the accuracy and efficiency of traditional dispensing systems decrease significantly. For example, in the management of multiple diseases such as diabetes mellitus complicated with hypertension and hyperlipidemia, when multiple drugs such as metformin, glimepiride, valsartan, amlodipine, and atorvastatin need to be dispensed simultaneously, the error rate of existing automated dispensing systems can reach 3% to 8%. Such medication errors not only involve confusion of drug types, but also dosage calculation deviations and failure of drug interaction warnings. The current mainstream approach to solving this problem is to introduce barcode scanning technology and a manual double-checking process, which increases manpower and extends medication preparation time to ensure safety. However, this solution based on manual intervention not only significantly reduces medication preparation efficiency, completing only 2 to 3 complex prescriptions every 10 minutes, but also fails to fundamentally eliminate the risk of human error, making it difficult to cope with the growing demand for personalized medication and ultimately limiting the full implementation of the precision medicine concept in daily pharmaceutical services.

[0004] In view of this, the present invention proposes a drug preparation method for achieving diversified drug formulation to solve the above problems. Summary of the Invention

[0005] To overcome the aforementioned deficiencies of the prior art and to achieve the above objectives, the present invention provides the following technical solution: a drug preparation method for achieving diversified drug formulation, comprising:

[0006] Step S1: Obtain the patient's prescription information, which includes drug type information, dosage information for each drug, and the patient's physiological characteristics information;

[0007] Step S2: Based on the dosage information and drug type information of each drug, determine the physical morphological characteristics and chemical stability characteristics of each drug, and combine them with the patient's physiological characteristics to determine the individualized adjustment factor for each drug;

[0008] Step S3: Determine the dispensing priority of each drug based on the individualized adjustment factor and the physical morphological characteristics of each drug, and generate a dispensing sequence table based on the dispensing priority;

[0009] Step S4: Based on the drug dispensing sequence list and the chemical stability characteristics of each drug, determine the isolation requirement level of each drug, and allocate an independent drug dispensing operation range for each drug according to the isolation requirement level;

[0010] Step S5: Within each dispensing operation interval, based on the dosage information and physical characteristics of each drug, determine the dosage segmentation pattern for each drug, and perform dosage segmentation for each drug according to the dosage segmentation pattern;

[0011] Step S6: Perform dynamic compatibility verification on the dose segmentation results, and after the verification is passed, combine and encapsulate all dose segmentation results to obtain the patient's customized drug combination.

[0012] Furthermore, the method for determining the individualized adjustment factor includes:

[0013] Obtain the patient's physiological characteristics, including age, weight, liver function indicators, and kidney function indicators.

[0014] For each drug, obtain its metabolic pathway characteristics and dose sensitivity characteristics from its drug type information;

[0015] Based on the characteristics of the metabolic pathway, the normalized weighted sum of the liver function index and kidney function index is used as the metabolic adjustment coefficient.

[0016] Based on the dose sensitivity characteristics, the normalized value of the product of the age value and the weight value is used as the sensitivity adjustment coefficient;

[0017] The product of the metabolic adjustment coefficient and the sensitivity adjustment coefficient is used as the individualized adjustment factor for each drug.

[0018] Furthermore, the method for determining the medication priority includes:

[0019] For each drug, obtain its physical morphology characteristics, including morphology category and solubility parameters, wherein the morphology category includes tablets, capsules, powders, and liquids;

[0020] Based on the morphology category, the priority weight value of tablets is set as the first weight value, the priority weight value of capsules is set as the second weight value, the priority weight value of powder is set as the third weight value, and the priority weight value of liquid is set as the fourth weight value, wherein the first weight value is greater than the second weight value, the second weight value is greater than the third weight value, and the third weight value is greater than the fourth weight value.

[0021] Based on the solubility parameter, the solubility parameter is compared with a preset solubility threshold. If the solubility parameter is greater than or equal to the preset solubility threshold, the priority weight value is increased by a preset increment value; otherwise, the priority weight value remains unchanged.

[0022] The product of the individualized adjustment factor and the adjusted priority weight value is used as the dispensing priority for each drug.

[0023] The medication dispensing order table is generated according to the medication dispensing priority from high to low.

[0024] Furthermore, the method for determining the isolation requirement level includes:

[0025] For each drug, obtain its volatility parameters, oxidation sensitivity parameters, and acid-base parameters from its chemical stability characteristics;

[0026] Based on the volatility parameter, the volatility parameter is compared with a preset volatility threshold. If the volatility parameter is greater than or equal to the preset volatility threshold, the volatility isolation factor is set to a first isolation value; otherwise, it is set to a second isolation value, wherein the first isolation value is greater than the second isolation value.

[0027] Based on the oxidation sensitivity parameter and the acid-base parameter, the normalized value of the absolute value of the difference between the oxidation sensitivity parameter and the preset oxidation threshold, and the sum of the absolute values ​​of the difference between the acid-base parameter and the preset acid-base threshold, is used as the chemical isolation factor.

[0028] The weighted sum of the volatile isolation factor and the chemical isolation factor is used as the isolation requirement level for each drug.

[0029] Furthermore, the method for determining the dose segmentation pattern includes:

[0030] For each drug, obtain its morphological category from its physical morphological characteristics and the target dose value from its dose information;

[0031] If the form type is tablet or capsule, the number of divisions is determined based on the ratio of the target dose value to the single tablet dose value, and the number of divisions is rounded to the nearest integer value as the tablet division mode or capsule division mode;

[0032] If the morphology is powder, the powder volume value is determined based on the ratio of the target dose value to the preset powder density value, and the ratio of the powder volume value to the preset minimum volume unit value is rounded to the nearest integer value as the powder segmentation mode.

[0033] If the morphology is liquid, the liquid volume value is determined based on the ratio of the target dose value to the preset liquid concentration value, and the ratio of the liquid volume value to the preset minimum droplet volume value is rounded to the nearest integer value as the liquid segmentation mode.

[0034] The tablet splitting mode, capsule splitting mode, powder splitting mode, or liquid splitting mode is used as the dosage splitting mode.

[0035] Furthermore, the method of dose-splitting each drug according to the dose-splitting pattern includes:

[0036] Within each dispensing operation interval, based on the dosage segmentation pattern, the segmentation tool type for each drug is determined, wherein the segmentation tool type includes mechanical cutting tools, powder metering tools, and liquid titration tools;

[0037] If the dosage segmentation mode is tablet segmentation mode or capsule segmentation mode, the tablet or capsule is cut into equal parts using the mechanical cutting tool, and the weight of the cut tablet or capsule fragments is verified. If the weight deviation is greater than the preset weight threshold, the cutting operation is repeated.

[0038] If the dosage splitting mode is the powder splitting mode, the powder metering tool is used to dispense the powder according to the powder volume value, and the volume of the dispensed powder is verified. If the volume deviation is greater than the preset volume threshold, the dispensing operation is repeated.

[0039] If the dosage segmentation mode is liquid segmentation mode, the liquid titration tool is used to perform titration according to the liquid volume value, and the liquid level height of the titrated liquid is verified. If the liquid level height deviation is greater than the preset height threshold, the titration operation is repeated.

[0040] Furthermore, the method for dynamically verifying the compatibility of the dose segmentation results includes:

[0041] For the dose segmentation results within all drug dispensing operation intervals, obtain the interaction parameters in the chemical stability characteristics of each drug.

[0042] Based on the interaction parameters, a compatibility risk value is determined for each pair of drugs, wherein the compatibility risk value is the absolute value of the difference between the interaction parameters and a preset interaction threshold.

[0043] If the compatibility risk value between any pair of drugs is greater than the preset risk threshold, the drug dispensing priority of the pair of drugs is adjusted in the drug dispensing sequence table to increase the physical isolation strength of their dispensing operation range, and the dosage is re-divided.

[0044] If the compatibility risk values ​​among all drugs are less than or equal to the preset risk threshold, then the dynamic compatibility verification is deemed successful.

[0045] Furthermore, the method of performing the combined packaging includes:

[0046] For the dose segmentation results within all drug dispensing operation intervals, the packaging form of each drug is determined based on the physical morphological characteristics of each drug, wherein the packaging form includes individual sealed bags, composite capsules and compartmentalized medicine boxes.

[0047] If the physical form is a tablet or capsule, then the individual sealed bag is selected as the packaging form;

[0048] If the physical form is powder or liquid, the packaging form is selected based on the isolation requirement level. If the isolation requirement level is greater than the preset isolation threshold, a composite capsule is selected as the packaging form; otherwise, a compartmentalized medicine box is selected as the packaging form.

[0049] According to the order in the medication dispensing order table, the dosage divisions of all drugs are packaged according to their respective packaging forms, and the packaged drug combinations are labeled, wherein the label includes the patient's name, drug type and administration time.

[0050] Furthermore, the encapsulation method of the composite capsule includes:

[0051] For each drug that needs to be packaged into a composite capsule, the volume value and chemical stability characteristics are obtained based on the results of its dose fractionation;

[0052] Based on the volume value, the volume specification of the composite capsule is determined, and based on the chemical stability characteristics, the type of inner wall isolation layer of the composite capsule is determined, wherein the type of inner wall isolation layer includes an antioxidant coating and an acid-base buffer coating.

[0053] The dose fractionation results are filled into the composite capsule, and during the filling process, separators are placed inside the composite capsule according to the proportion of the volume value;

[0054] The filled composite capsule is sealed, and the sealing strength is verified. If the sealing strength is less than a preset strength threshold, the sealing operation is repeated.

[0055] Furthermore, the allocation of independent dispensing operation areas for each drug based on the isolation requirement level includes:

[0056] Obtain the operating space information of the dispensing equipment, wherein the operating space information includes the total area of ​​the operating space and the number of partition units;

[0057] Based on the isolation requirement level, the total area value is divided according to the proportion of the isolation requirement level to obtain the area value of each medication dispensing operation area;

[0058] For each dispensing operation area, based on the number of partition units and the area value, the number of partition units configured for each dispensing operation area is determined, and physical isolation walls are set according to the number of partition units configured. The material of the physical isolation walls is selected according to the isolation requirement level, including transparent isolation panels and opaque isolation panels.

[0059] If the required isolation level is greater than the preset isolation threshold, the opaque isolation panel is selected as the physical isolation wall; otherwise, the transparent isolation panel is selected as the physical isolation wall.

[0060] The technical effects and advantages of the drug preparation method for achieving diversified drug formulation according to the present invention are as follows:

[0061] This invention, through processing patient prescription information and combining it with the physical and chemical stability characteristics of drugs, establishes individualized adjustment factors to achieve precise responses to patients' physiological characteristics. These individualized adjustment factors comprehensively consider the matching degree between patients' age, weight, liver and kidney function, and other physiological indicators with drug metabolic pathways and dose sensitivity, enabling drug preparation to move from standardization to precision and effectively reducing the risk of adverse reactions. The drug prioritization mechanism and sequence list established based on drug characteristics solve the problem of process chaos when multiple drugs are prepared simultaneously, providing scientific guidance for subsequent drug preparation operations. The isolation requirement levels designed based on chemical stability characteristics accurately assess parameters such as volatility, oxidation sensitivity, and acidity / alkalinity, achieving precise isolation of drugs with different chemical properties, avoiding potential mutual interference and chemical reactions during drug preparation, and ensuring drug quality and therapeutic efficacy. For the characteristics of different drug forms (tablets, capsules, powders, liquids), this invention designs differentiated dosage segmentation modes and verification methods. By selecting appropriate segmentation tools and implementing strict verification procedures, precise and controllable dosage is ensured. Dynamic compatibility verification mechanisms and intelligent packaging strategies ensure the safety and stability of drug combinations, enabling the drug preparation system to flexibly respond to the risks of interactions between drugs. Attached Figure Description

[0062] Figure 1 This is a schematic diagram of a drug preparation method for achieving diversified drug formulation according to the present invention;

[0063] Figure 2 This is a schematic diagram of a drug dispensing system for achieving diversified drug configuration according to the present invention. Detailed Implementation

[0064] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0065] Example 1

[0066] Please see Figure 1 As shown in the figure, this embodiment provides a drug preparation method for achieving diversified drug formulation, including:

[0067] Step S1: Obtain the patient's prescription information, which includes drug type information, dosage information for each drug, and the patient's physiological characteristics information;

[0068] Prescription information includes information on the types of medications the patient needs to take (such as drug name, drug type, formulation type, etc.), dosage information for each drug (such as daily dosage, dosage per dose, frequency of administration, etc.), and the patient's physiological characteristics (such as age, weight, liver function indicators, kidney function indicators, etc.). In this embodiment, after obtaining the prescription information, it is parsed and categorized to extract drug type information, dosage information, and patient physiological characteristics, preparing for the subsequent personalized medication dispensing process. Drug type information includes drug name, drug metabolic pathway characteristics, and dose sensitivity characteristics; dosage information includes the target dose value for each drug; physiological characteristics information includes the patient's age, weight, liver function indicators, and kidney function indicators.

[0069] Step S2: Based on the dosage information and drug type information of each drug, determine the physical morphological characteristics and chemical stability characteristics of each drug, and combine them with the patient's physiological characteristics to determine the individualized adjustment factor for each drug;

[0070] The physical characteristics of a drug refer to its form (such as tablets, capsules, powders, and liquids) and solubility parameters; chemical stability characteristics refer to its volatility, oxidation sensitivity, acidity / alkalinity, and interaction parameters. The dispensing system queries a drug database to obtain the physical and chemical stability characteristics of each drug in a prescription, providing fundamental data support for the subsequent dispensing process.

[0071] A patient's physiological characteristics influence the metabolism and absorption of drugs in the body. Therefore, it is necessary to determine individualized adjustment factors for each drug based on the patient's physiological characteristics to achieve personalized drug formulation. The method for determining individualized adjustment factors includes: obtaining the patient's age, weight, liver function indicators, and kidney function indicators from their physiological characteristics; for each drug, obtaining its metabolic pathway characteristics and dose sensitivity characteristics from its drug type information; based on the metabolic pathway characteristics, normalizing the weighted sum of the liver function indicators and kidney function indicators as the metabolic adjustment coefficient; based on the dose sensitivity characteristics, normalizing the product of the age and weight values ​​as the sensitivity adjustment coefficient; and multiplying the metabolic adjustment coefficient and the sensitivity adjustment coefficient as the individualized adjustment factor for each drug.

[0072] In one specific implementation of this invention, the individualized adjustment factor is expressed by the formula:

[0073] ;

[0074] ;

[0075] ;

[0076] In the formula, For the first Individualized adjustment factors for this type of drug; For the first Metabolic adjustment coefficient of a drug; For the first Sensitivity adjustment coefficient for a drug; This is a liver function weighting coefficient, determined based on the characteristics of the drug's metabolic pathway. This is the renal function weighting coefficient, determined based on the characteristics of the drug's metabolic pathway; These are the patient's liver function indicators; These are the patient's renal function index values; The patient's age value; The patient's weight value; This is the normalization function.

[0077] For example, for drug A, which is primarily metabolized by the liver, its liver function weighting coefficient is 0.8, and its kidney function weighting coefficient is 0.2; for drug B, which is primarily excreted by the kidneys, its liver function weighting coefficient is 0.3, and its kidney function weighting coefficient is 0.7. Assuming a patient's liver function index is 85 (normal range 80-120), kidney function index is 60 (normal range 60-100), age is 65 years, and weight is 70 kg, then: the metabolic adjustment coefficient q for drug A is: ;

[0078] Sensitivity adjustment factor for drug A: ;

[0079] Individualized adjustment factors for drug A: ;

[0080] Metabolic adjustment factor of drug B: ;

[0081] Sensitivity adjustment factor for drug B: ;

[0082] Individualized adjustment factors for drug B: ;

[0083] The closer the individualized adjustment factor is to 1, the more the drug's metabolism and absorption process conforms to the standard conditions, and the smaller the dose adjustment required; the closer the individualized adjustment factor is to 0, the more the drug's metabolism and absorption process deviates from the standard conditions, and the larger the dose adjustment required.

[0084] Step S3: Determine the dispensing priority of each drug based on the individualized adjustment factor and the physical morphological characteristics of each drug, and generate a dispensing sequence table based on the dispensing priority;

[0085] Medication priority refers to the order in which various drugs are prepared during the dispensing process. A higher priority drug is prepared first. Determining the medication priority requires consideration of the drugs' physical characteristics and individualized adjustment factors to ensure the efficiency and safety of the dispensing process.

[0086] The method for determining the dispensing priority includes: for each drug, obtaining its physical morphological characteristics, including its morphological category and solubility parameter; based on the morphological category, setting the priority weight value of tablets as the first weight value, capsules as the second weight value, powders as the third weight value, and liquids as the fourth weight value, wherein the first weight value is greater than the second weight value, the second weight value is greater than the third weight value, and the third weight value is greater than the fourth weight value; based on the solubility parameter, comparing the solubility parameter with a preset solubility threshold, if the solubility parameter is greater than or equal to the preset solubility threshold, increasing the priority weight value by a preset increment value, otherwise keeping the priority weight value unchanged; and using the product of the individualized adjustment factor and the adjusted priority weight value as the dispensing priority for each drug.

[0087] In this embodiment, the first weight value is 4.0, the second weight value is 3.0, the third weight value is 2.0, and the fourth weight value is 1.0; the preset solubility threshold is 0.5 (the solubility parameter ranges from 0 to 1, and the larger the value, the better the solubility); and the preset increment value is 0.5.

[0088] For example, for drug C, which is a tablet and has a solubility parameter of 0.7, its individualized adjustment factor is 0.615, then:

[0089] Priority weight value: 4.0; Solubility parameter 0.7 > preset solubility threshold 0.5, adjusted priority weight value: Medication dispensing priority: ;

[0090] For drug D, which is a powder and has a solubility parameter of 0.3, its individualized adjustment factor is 0.287. Then:

[0091] Priority weight value: 2.0; Solubility parameter 0.3 < preset solubility threshold 0.5, adjusted priority weight value: 2.0; Dispensing priority: ;

[0092] A dispensing order table is generated based on the dispensing priority from highest to lowest. In this example, drug C has a higher dispensing priority than drug D, therefore drug C is listed before drug D in the dispensing order table.

[0093] Step S4: Based on the drug dispensing sequence table and the chemical stability characteristics of each drug, determine the isolation requirement level of each drug, and allocate an independent drug dispensing operation range for each drug according to the isolation requirement level;

[0094] The isolation requirement level refers to the degree of physical isolation required for a drug during the dispensing process. The higher the isolation requirement level, the more stringent the physical isolation required between the drug and other drugs. Determining the isolation requirement level requires consideration of the drug's chemical stability characteristics to ensure that no adverse chemical reactions or interference occur between drugs during the dispensing process.

[0095] The method for determining the isolation requirement level includes: for each drug, obtaining its volatility parameter, oxidation sensitivity parameter, and acid-base parameter from its chemical stability characteristics; based on the volatility parameter, comparing the volatility parameter with a preset volatility threshold; if the volatility parameter is greater than or equal to the preset volatility threshold, setting the volatility isolation factor as the first isolation value; otherwise, setting it as the second isolation value, where the first isolation value is greater than the second isolation value; based on the oxidation sensitivity parameter and the acid-base parameter, normalizing the sum of the absolute values ​​of the difference between the oxidation sensitivity parameter and the preset oxidation threshold, and the absolute values ​​of the difference between the acid-base parameter and the preset acid-base threshold, and using this as the chemical isolation factor; and using the weighted sum of the volatility isolation factor and the chemical isolation factor as the isolation requirement level for each drug.

[0096] In this embodiment, the first isolation value is 0.8, the second isolation value is 0.2; the preset volatility threshold is 0.6 (the volatility parameter ranges from 0 to 1, and the larger the value, the stronger the volatility); the preset oxidation threshold is 0.5 (the oxidation sensitivity parameter ranges from 0 to 1, and the larger the value, the stronger the oxidation sensitivity); and the preset acid-base threshold is 7.0 (the acid-base parameter ranges from 0 to 14, representing the pH value of the drug).

[0097] In one specific implementation of this invention, the isolation requirement level is expressed by the formula:

[0098] ;

[0099] ;

[0100] ;

[0101] In the formula, For the first The isolation requirement level for this type of medicine; This is the volatility weighting coefficient, with a value of 0.6; This is the chemical isolation weighting coefficient, with a value of 0.4; For the first The volatile isolation factor of drug i; CIFi is the chemical isolation factor of drug i. For the first Volatility parameters of the drug; For the first Oxidation sensitivity parameters of a drug; For the first The acid-base properties of the drug; This is the normalization function.

[0102] For example, for a drug with a volatility parameter of 0.8, an oxidation sensitivity parameter of 0.3, and an acid-base parameter of 5.5, its isolation requirement level is calculated as follows:

[0103] Volatile isolation factor: 0.8 > 0.6, then It is 0.8

[0104] Chemical isolation factor: ;

[0105] Quarantine requirement level: ;

[0106] Each drug is assigned a separate dispensing area based on the isolation requirement level. The higher the isolation requirement level, the higher the isolation intensity of the dispensing area.

[0107] Step S5: Within each dispensing operation interval, based on the dosage information and physical characteristics of each drug, determine the dosage segmentation pattern for each drug, and perform dosage segmentation for each drug according to the dosage segmentation pattern;

[0108] Dosage fractionation refers to the method of dividing a drug according to a target dose. The determination of the dosage fractionation method needs to take into account the physical characteristics of the drug and dosage information to ensure the accuracy and feasibility of dosage fractionation.

[0109] The method for determining the dosage segmentation pattern includes: for each drug, obtaining the morphological category from its physical morphological characteristics and the target dose value from its dosage information; if the morphological category is tablet or capsule, determining the number of segments based on the ratio of the target dose value to the single tablet dose value, and rounding the number of segments to the nearest integer value, as the tablet segmentation pattern or capsule segmentation pattern; if the morphological category is powder, determining the powder volume value based on the ratio of the target dose value to the preset powder density value, and rounding the ratio of the powder volume value to the preset minimum volume unit value to the nearest integer value, as the powder segmentation pattern; if the morphological category is liquid, determining the liquid volume value based on the ratio of the target dose value to the preset liquid concentration value, and rounding the ratio of the liquid volume value to the preset minimum droplet volume value to the nearest integer value, as the liquid segmentation pattern.

[0110] In this embodiment, the preset powder density value is 0.8 g / ml; the preset minimum volume unit value is 0.1 ml; the preset liquid concentration value is 10 mg / ml; and the preset minimum droplet volume value is 0.05 ml.

[0111] For example, for a drug with a tablet form, a single tablet dose of 10 mg, and a target dose of 15 mg, the dose splitting pattern is calculated as follows:

[0112] Number of portions: 15mg ÷ 10mg = 1.5;

[0113] Tablet splitting mode: rounded to the nearest integer value, i.e., 2;

[0114] For drugs in powder form with a target dose of 40 mg, the dose fractionation pattern is calculated as follows:

[0115] Powder volume value: 40mg ÷ 0.8g / ml = 0.05ml;

[0116] Powder dispensing method: 0.05ml ÷ 0.1ml = 0.5, rounded to the nearest integer value, i.e., 1;

[0117] The method of dose-splitting each drug according to the dose-splitting pattern includes: within each drug preparation operation interval, determining the type of splitting tool for each drug based on the dose-splitting pattern, where the splitting tool type includes mechanical cutting tools, powder metering tools, and liquid titration tools; selecting the appropriate splitting tool according to different dose-splitting patterns, and verifying the splitting results to ensure that the splitting results meet the expected dose requirements.

[0118] Step S6: Perform dynamic compatibility verification on the dose segmentation results, and after the verification is passed, combine and encapsulate all dose segmentation results to obtain the patient's customized drug combination.

[0119] Dynamic compatibility verification refers to the real-time verification of the chemical compatibility between different drugs during the drug preparation process, to ensure that different drugs will not produce adverse chemical reactions or interfere with each other after being combined and packaged.

[0120] The dynamic compatibility verification method includes: obtaining the interaction parameters in the chemical stability characteristics of each drug for the dose segmentation results within all drug dispensing operation intervals; determining the compatibility risk value between each pair of drugs based on the interaction parameters, where the compatibility risk value is the absolute value of the difference between the interaction parameter and the preset interaction threshold; if the compatibility risk value between any pair of drugs is greater than the preset risk threshold, the drug dispensing priority of that pair of drugs is adjusted in the drug dispensing sequence table to increase the physical isolation strength of its drug dispensing operation interval, and the dose segmentation is re-performed; if the compatibility risk value between all drugs is less than or equal to the preset risk threshold, the dynamic compatibility verification is deemed to have passed.

[0121] In this embodiment, the preset interaction threshold is 0.3 (the interaction parameter ranges from 0 to 1, and the larger the value, the stronger the interaction); the preset risk threshold is 0.4.

[0122] Combination packaging refers to the combination and packaging of all drug dosage fractions that have passed dynamic compatibility verification to form a customized drug combination for the patient. Combination packaging methods include: for dosage fractions within all dispensing intervals, determining the packaging form for each drug based on its physical characteristics, including individual sealed bags, composite capsules, and compartmentalized pillboxes; selecting the appropriate packaging form based on different physical characteristics and isolation requirements; and labeling the packaged drug combination with information including the patient's name, drug type, and administration time.

[0123] For drugs that need to be packaged into composite capsules, the packaging method for composite capsules includes: for each drug that needs to be packaged into composite capsules, obtaining volume values ​​and chemical stability characteristics based on its dose fractionation results; determining the volume specifications of the composite capsule based on the volume values, and determining the type of inner wall isolation layer of the composite capsule based on the chemical stability characteristics, wherein the inner wall isolation layer type includes an antioxidant coating and an acid-base buffer coating; filling the composite capsule with the dose fractionation results, and during the filling process, setting separators inside the composite capsule according to the proportion of the volume values; sealing the filled composite capsule, and verifying the sealing strength; if the sealing strength is less than a preset strength threshold, the sealing operation is repeated.

[0124] In this embodiment, an independent dispensing operation area is allocated for each drug according to the isolation requirement level. This includes: obtaining the operating space information of the dispensing equipment, which includes the total area value and the number of partition units; dividing the total area value according to the isolation requirement level to obtain the area value of each dispensing operation area; for each dispensing operation area, determining the number of partition units configured for each dispensing operation area based on the number of partition units and the area value, and setting physical isolation walls according to the number of partition units configured, wherein the material of the physical isolation wall is selected according to the isolation requirement level, including transparent isolation panels and opaque isolation panels; if the isolation requirement level is greater than a preset isolation threshold, an opaque isolation panel is selected as the physical isolation wall, otherwise a transparent isolation panel is selected as the physical isolation wall.

[0125] This embodiment, through processing patient prescription information and combining the physical and chemical stability characteristics of drugs, establishes individualized adjustment factors to achieve precise responses to patients' physiological characteristics. These individualized adjustment factors comprehensively consider the matching degree between patients' age, weight, liver and kidney function, and other physiological indicators with drug metabolic pathways and dose sensitivity, enabling drug preparation to move from standardization to precision and effectively reducing the risk of adverse reactions. The drug prioritization mechanism and sequence list established based on drug characteristics solve the problem of process chaos when multiple drugs are prepared simultaneously, providing scientific guidance for subsequent drug preparation operations. The isolation requirement level system designed based on chemical stability characteristics accurately assesses parameters such as volatility, oxidation sensitivity, and acidity / alkalinity, achieving precise isolation of drugs with different chemical properties, avoiding potential mutual interference and chemical reactions during drug preparation, and ensuring drug quality and therapeutic efficacy. For the characteristics of different drug forms (tablets, capsules, powders, liquids), this invention designs differentiated dosage segmentation modes and verification methods. By selecting appropriate segmentation tools and implementing strict verification procedures, precise and controllable dosage is ensured. Dynamic compatibility verification mechanisms and intelligent packaging strategies ensure the safety and stability of drug combinations, enabling the drug preparation system to flexibly respond to the risks of interactions between drugs.

[0126] Example 2

[0127] Please see Figure 2 As shown, parts not described in detail in this embodiment are described in Embodiment 1. A drug dispensing system for achieving diversified drug formulation is provided, including:

[0128] Data acquisition module: Acquires patient prescription information, including drug type information, dosage information for each drug, and patient physiological characteristic information;

[0129] Adjustment determination module: Based on the dosage information and drug type information of each drug, determine the physical and chemical stability characteristics of each drug, and combine the patient's physiological characteristics information to determine the individualized adjustment factors of each drug;

[0130] Sequence construction module: Based on the individualized adjustment factor and the physical morphological characteristics of each drug, determine the dispensing priority of each drug, and generate a dispensing sequence table based on the dispensing priority;

[0131] Allocation Interval Module: Based on the drug dispensing sequence table and the chemical stability characteristics of each drug, determine the isolation requirement level of each drug, and allocate an independent drug dispensing operation interval for each drug according to the isolation requirement level;

[0132] Segmentation module: Within each dispensing operation interval, based on the dosage information and physical characteristics of each drug, the dosage segmentation mode of each drug is determined, and the dosage of each drug is segmented according to the dosage segmentation mode;

[0133] Verification and packaging module: Performs dynamic compatibility verification on the dose segmentation results, and after successful verification, combines and packages all dose segmentation results to obtain a customized drug combination for the patient.

[0134] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

[0135] It should be noted that, in this document, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Unless otherwise specified, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes said element.

[0136] In the description of this invention, it should be understood that the terms "first," "second," etc., are used only for distinguishing descriptions and should not be construed as indicating or implying relative importance.

[0137] In the description of this invention, unless otherwise stated, "a plurality of" means two or more.

[0138] In the description of this invention, "several" means one or more, and "a large number" means two or more.

[0139] In the description of this specification, references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples.

[0140] All formulas in this manual are dimensionless and calculated numerically. The formulas are derived from software simulations based on a large amount of collected data to obtain the most recent real-world results. The preset parameters and thresholds in the formulas are set by those skilled in the art according to the actual situation.

[0141] Although embodiments of the invention have been shown and described, those skilled in the art will understand that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the claims and their equivalents.

Claims

1. A method for dispensing medicines to achieve diversified formulation, characterized in that, include: Step S1: Obtain the patient's prescription information, which includes drug type information, dosage information for each drug, and the patient's physiological characteristics information; Step S2: Based on the dosage information and drug type information of each drug, determine the physical morphological characteristics and chemical stability characteristics of each drug, and combine them with the patient's physiological characteristics to determine the individualized adjustment factor for each drug; Step S3: Determine the dispensing priority of each drug based on the individualized adjustment factor and the physical morphological characteristics of each drug, and generate a dispensing sequence table based on the dispensing priority; Step S4: Based on the drug dispensing sequence list and the chemical stability characteristics of each drug, determine the isolation requirement level of each drug, and allocate an independent drug dispensing operation range for each drug according to the isolation requirement level; Step S5: Within each dispensing operation interval, based on the dosage information and physical characteristics of each drug, determine the dosage segmentation pattern for each drug, and perform dosage segmentation for each drug according to the dosage segmentation pattern; Step S6: Perform dynamic compatibility verification on the dose segmentation results, and after the verification is passed, combine and encapsulate all dose segmentation results to obtain the patient's customized drug combination.

2. The drug preparation method for achieving diversified drug formulation according to claim 1, characterized in that, The method for determining the individualized adjustment factor includes: Obtain the patient's physiological characteristics, including age, weight, liver function indicators, and kidney function indicators. For each drug, obtain its metabolic pathway characteristics and dose sensitivity characteristics from its drug type information; Based on the characteristics of the metabolic pathway, the normalized weighted sum of the liver function index and kidney function index is used as the metabolic adjustment coefficient. Based on the dose sensitivity characteristics, the normalized value of the product of the age value and the weight value is used as the sensitivity adjustment coefficient; The product of the metabolic adjustment coefficient and the sensitivity adjustment coefficient is used as the individualized adjustment factor for each drug.

3. The drug preparation method for achieving diversified drug formulation according to claim 1, characterized in that, The method for determining the medication priority includes: For each drug, obtain its physical morphology characteristics, including morphology category and solubility parameters, wherein the morphology category includes tablets, capsules, powders, and liquids; Based on the morphology category, the priority weight value of tablets is set as the first weight value, the priority weight value of capsules is set as the second weight value, the priority weight value of powder is set as the third weight value, and the priority weight value of liquid is set as the fourth weight value, wherein the first weight value is greater than the second weight value, the second weight value is greater than the third weight value, and the third weight value is greater than the fourth weight value. Based on the solubility parameter, the solubility parameter is compared with a preset solubility threshold. If the solubility parameter is greater than or equal to the preset solubility threshold, the priority weight value is increased by a preset increment value; otherwise, the priority weight value remains unchanged. The product of the individualized adjustment factor and the adjusted priority weight value is used as the dispensing priority for each drug. The medication dispensing order table is generated according to the medication dispensing priority from high to low.

4. The drug dispensing method for achieving diversified drug configuration according to claim 1, characterized in that, The methods for determining the isolation requirement level include: For each drug, obtain its volatility parameters, oxidation sensitivity parameters, and acid-base parameters from its chemical stability characteristics; Based on the volatility parameter, the volatility parameter is compared with a preset volatility threshold. If the volatility parameter is greater than or equal to the preset volatility threshold, the volatility isolation factor is set to a first isolation value; otherwise, it is set to a second isolation value, wherein the first isolation value is greater than the second isolation value. Based on the oxidation sensitivity parameter and the acid-base parameter, the normalized value of the absolute value of the difference between the oxidation sensitivity parameter and the preset oxidation threshold, and the sum of the absolute values ​​of the difference between the acid-base parameter and the preset acid-base threshold, is used as the chemical isolation factor. The weighted sum of the volatile isolation factor and the chemical isolation factor is used as the isolation requirement level for each drug.

5. A method for dispensing medicines to achieve diversified formulation according to claim 1, characterized in that, The method for determining the dose segmentation pattern includes: For each drug, obtain its morphological category from its physical morphological characteristics and the target dose value from its dose information; If the form type is tablet or capsule, the number of divisions is determined based on the ratio of the target dose value to the single tablet dose value, and the number of divisions is rounded to the nearest integer value as the tablet division mode or capsule division mode; If the morphology is powder, the powder volume value is determined based on the ratio of the target dose value to the preset powder density value, and the ratio of the powder volume value to the preset minimum volume unit value is rounded to the nearest integer value as the powder segmentation mode. If the morphology is liquid, the liquid volume value is determined based on the ratio of the target dose value to the preset liquid concentration value, and the ratio of the liquid volume value to the preset minimum droplet volume value is rounded to the nearest integer value as the liquid segmentation mode. The tablet splitting mode, capsule splitting mode, powder splitting mode, or liquid splitting mode is used as the dosage splitting mode.

6. A method for dispensing medicines to achieve diversified formulations according to claim 5, characterized in that, The method of dose-splitting each drug according to the dose-splitting pattern includes: Within each dispensing operation interval, based on the dosage segmentation pattern, the segmentation tool type for each drug is determined, wherein the segmentation tool type includes mechanical cutting tools, powder metering tools, and liquid titration tools; If the dosage segmentation mode is tablet segmentation mode or capsule segmentation mode, the tablet or capsule is cut into equal parts using the mechanical cutting tool, and the weight of the cut tablet or capsule fragments is verified. If the weight deviation is greater than the preset weight threshold, the cutting operation is repeated. If the dosage splitting mode is the powder splitting mode, the powder metering tool is used to dispense the powder according to the powder volume value, and the volume of the dispensed powder is verified. If the volume deviation is greater than the preset volume threshold, the dispensing operation is repeated. If the dosage segmentation mode is liquid segmentation mode, the liquid titration tool is used to perform titration according to the liquid volume value, and the liquid level height of the titrated liquid is verified. If the liquid level height deviation is greater than the preset height threshold, the titration operation is repeated.

7. A method for dispensing medicines to achieve diversified formulation according to claim 1, characterized in that, The methods for dynamically verifying the compatibility of dose segmentation results include: For the dose segmentation results within all drug dispensing operation intervals, obtain the interaction parameters in the chemical stability characteristics of each drug. Based on the interaction parameters, a compatibility risk value is determined for each pair of drugs, wherein the compatibility risk value is the absolute value of the difference between the interaction parameters and a preset interaction threshold. If the compatibility risk value between any pair of drugs is greater than the preset risk threshold, the drug dispensing priority of the pair of drugs is adjusted in the drug dispensing sequence table to increase the physical isolation strength of their dispensing operation range, and the dosage is re-divided. If the compatibility risk values ​​among all drugs are less than or equal to the preset risk threshold, then the dynamic compatibility verification is deemed successful.

8. The method for dispensing medicines to achieve diversified formulation according to claim 1, characterized in that, The methods for performing combined packaging include: For the dose segmentation results within all drug dispensing operation intervals, the packaging form of each drug is determined based on the physical morphological characteristics of each drug, wherein the packaging form includes individual sealed bags, composite capsules and compartmentalized medicine boxes. If the physical form is a tablet or capsule, then the individual sealed bag is selected as the packaging form; If the physical form is powder or liquid, the packaging form is selected based on the isolation requirement level. If the isolation requirement level is greater than the preset isolation threshold, a composite capsule is selected as the packaging form; otherwise, a compartmentalized medicine box is selected as the packaging form. According to the order in the medication dispensing order table, the dosage divisions of all drugs are packaged according to their respective packaging forms, and the packaged drug combinations are labeled, wherein the label includes the patient's name, drug type and administration time.

9. A method for dispensing medicines to achieve diversified formulation according to claim 8, characterized in that, The encapsulation method of the composite capsule includes: For each drug that needs to be packaged into a composite capsule, the volume value and chemical stability characteristics are obtained based on the results of its dose fractionation; Based on the volume value, the volume specification of the composite capsule is determined, and based on the chemical stability characteristics, the type of inner wall isolation layer of the composite capsule is determined, wherein the type of inner wall isolation layer includes an antioxidant coating and an acid-base buffer coating. The dose fractionation results are filled into the composite capsule, and during the filling process, separators are placed inside the composite capsule according to the proportion of the volume value; The filled composite capsule is sealed, and the sealing strength is verified. If the sealing strength is less than a preset strength threshold, the sealing operation is repeated.

10. A method for dispensing medicines to achieve diversified formulation according to claim 1, characterized in that, The allocation of independent dispensing operation areas for each drug based on the isolation requirement level includes: Obtain the operating space information of the dispensing equipment, wherein the operating space information includes the total area of ​​the operating space and the number of partition units; Based on the isolation requirement level, the total area value is divided according to the proportion of the isolation requirement level to obtain the area value of each medication dispensing operation area; For each dispensing operation area, based on the number of partition units and the area value, the number of partition units configured for each dispensing operation area is determined, and physical isolation walls are set according to the number of partition units configured. The material of the physical isolation walls is selected according to the isolation requirement level, including transparent isolation panels and opaque isolation panels. If the required isolation level is greater than the preset isolation threshold, the opaque isolation panel is selected as the physical isolation wall; otherwise, the transparent isolation panel is selected as the physical isolation wall.

Images